Novo Nordisk, the pharmaceutical giant behind groundbreaking drugs like Ozempic and Wegovy, is embarking on a new frontier in medical research with the funding of a cutting-edge supercomputer.
The Novo Nordisk Foundation has allocated resources to Eviden, a French computing company, to construct a state-of-the-art supercomputer powered by Nvidia's artificial intelligence technology. The primary objective of this initiative is to revolutionize the discovery of new medicines and treatments.
